Form 8-K · Current report
General Motors 8-K, filed Oct 20, 2026
- Filed
- CIK
- 0001467858
- Accession no.
- 0001467858-26-000056
Summary
General Motors reported third-quarter 2026 revenue of $50.0 billion, net income attributable to stockholders of $3.3 billion, and EBIT-adjusted of $4.1 billion, and narrowed its full-year 2026 EBIT-adjusted guidance to $14.5–15.5 billion. GM's board approved a new $20 billion multi-year share repurchase authorization, after the company completed the $6.0 billion program announced in January 2026, and declared a quarterly dividend of $0.18 per share.
Key points
- Third-quarter 2026 revenue was $50.0 billion, up 2.9% from $48.6 billion a year earlier, with EBIT-adjusted of $4.1 billion and EPS-diluted-adjusted of $3.70.
- Full-year 2026 guidance was narrowed to EBIT-adjusted of $14.5–15.5 billion, adjusted automotive free cash flow of $11.5–12.5 billion, and EPS-diluted-adjusted of $12.75–13.75.
- The new $20 billion share repurchase authorization has no expiration date and may be suspended or discontinued at the company's discretion.
- The quarterly dividend of $0.18 per share is payable December 17, 2026, to holders of record at the close of trading on December 4, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 Results of Operations and Financial Condition On October 20, 2026, General Motors Company (GM) issued a news release and supplemental materials on the subject of its 2026 third quarter consolidated earnings. The news release and supplemental materials are attached as Exhibit 99.1. Charts furnished to securities analysts in connection with GM's 2026 third quarter consolidated earnings release are available on GM's website at www.gm.com/investors/earnings-releases.html. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.